PL2900254T3 - Alfa-1 mikroglobulina do użycia w leczeniu chorób związanych z mitochondriami - Google Patents
Alfa-1 mikroglobulina do użycia w leczeniu chorób związanych z mitochondriamiInfo
- Publication number
- PL2900254T3 PL2900254T3 PL13759995T PL13759995T PL2900254T3 PL 2900254 T3 PL2900254 T3 PL 2900254T3 PL 13759995 T PL13759995 T PL 13759995T PL 13759995 T PL13759995 T PL 13759995T PL 2900254 T3 PL2900254 T3 PL 2900254T3
- Authority
- PL
- Poland
- Prior art keywords
- microglobulin
- mitochondria
- alpha
- treatment
- related diseases
- Prior art date
Links
- 102000003966 Alpha-1-microglobulin Human genes 0.000 title 1
- 101800001761 Alpha-1-microglobulin Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000003470 mitochondria Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1722—Plasma globulins, lactoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201270538 | 2012-09-05 | ||
| DKPA201270557 | 2012-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2900254T3 true PL2900254T3 (pl) | 2017-02-28 |
Family
ID=49162118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13759995T PL2900254T3 (pl) | 2012-09-05 | 2013-09-04 | Alfa-1 mikroglobulina do użycia w leczeniu chorób związanych z mitochondriami |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10226507B2 (en:Method) |
| EP (1) | EP2900254B1 (en:Method) |
| JP (2) | JP2015533790A (en:Method) |
| KR (1) | KR20150047510A (en:Method) |
| CN (1) | CN104661673A (en:Method) |
| AU (1) | AU2013311714C1 (en:Method) |
| BR (1) | BR112015003957A2 (en:Method) |
| CA (1) | CA2881321A1 (en:Method) |
| DK (1) | DK2900254T3 (en:Method) |
| EA (1) | EA028963B1 (en:Method) |
| ES (1) | ES2599034T3 (en:Method) |
| HR (1) | HRP20161364T1 (en:Method) |
| HU (1) | HUE030559T2 (en:Method) |
| IN (1) | IN2015DN00515A (en:Method) |
| MX (1) | MX357656B (en:Method) |
| NZ (1) | NZ629621A (en:Method) |
| PL (1) | PL2900254T3 (en:Method) |
| PT (1) | PT2900254T (en:Method) |
| SG (1) | SG11201500669SA (en:Method) |
| WO (1) | WO2014037390A1 (en:Method) |
| ZA (1) | ZA201500547B (en:Method) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016204360A (ja) * | 2015-02-25 | 2016-12-08 | エー１エム ファーマ エービーＡ１Ｍ Ｐｈａｒｍａ ＡＢ | 放射性核種療法における腎臓の保護に用いるためのアルファ−１−ミクログロブリン |
| CA3014850A1 (en) * | 2016-02-25 | 2017-08-31 | A1M Pharma Ab | Alpha-1-microglobulin for use in the protection of kidneys in connection with use of contrast media |
| EA039776B1 (ru) * | 2016-03-18 | 2022-03-11 | Гард Терапьютикс Интернэшнл Айби | Новые белки, полученные из альфа-1-микроглобулина, и их применение |
| GB2566516A (en) | 2017-09-15 | 2019-03-20 | Univ Oxford Innovation Ltd | Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria |
| CN109867717A (zh) * | 2019-04-01 | 2019-06-11 | 山西瑞亚力生物技术有限公司 | 一种血浆中α1微球蛋白的提取方法 |
| CN110452980B (zh) * | 2019-09-23 | 2023-07-28 | 武汉儿童医院 | 一种线粒体脑肌病诊断试剂盒及应用 |
| WO2021062007A1 (en) * | 2019-09-25 | 2021-04-01 | Cytegen Corp. | Treatment of mitochondrial deficits and age-related diseases using blood products |
| CN115575646B (zh) * | 2022-11-21 | 2023-04-28 | 四川大学华西医院 | 一种代谢标志物组在制备预测癫痫发作的试剂盒中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004292775A1 (en) * | 2003-11-26 | 2005-06-09 | Sanofi-Aventis Deutschland Gmbh | Tubular proteinuria as an indicator for elevated cardiovascular risk |
| PL2111555T3 (pl) * | 2007-02-12 | 2013-10-31 | A1M Pharma Ab | Diagnostyka stanu przedrzucawkowego |
| PL2300614T3 (pl) * | 2008-02-04 | 2016-04-29 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Sposoby i kompozycje do leczenia zaburzeń mitochondrialnych |
| WO2010006809A2 (en) | 2008-07-18 | 2010-01-21 | Akerstroem Bo | Medical use of the radical scavenger and antioxidant alpha-1-microglobulin |
-
2013
- 2013-09-04 HR HRP20161364TT patent/HRP20161364T1/hr unknown
- 2013-09-04 CA CA2881321A patent/CA2881321A1/en not_active Abandoned
- 2013-09-04 SG SG11201500669SA patent/SG11201500669SA/en unknown
- 2013-09-04 BR BR112015003957A patent/BR112015003957A2/pt not_active Application Discontinuation
- 2013-09-04 PT PT137599957T patent/PT2900254T/pt unknown
- 2013-09-04 US US14/423,260 patent/US10226507B2/en not_active Expired - Fee Related
- 2013-09-04 PL PL13759995T patent/PL2900254T3/pl unknown
- 2013-09-04 IN IN515DEN2015 patent/IN2015DN00515A/en unknown
- 2013-09-04 JP JP2015530375A patent/JP2015533790A/ja active Pending
- 2013-09-04 EA EA201590503A patent/EA028963B1/ru not_active IP Right Cessation
- 2013-09-04 ES ES13759995.7T patent/ES2599034T3/es active Active
- 2013-09-04 KR KR1020157005748A patent/KR20150047510A/ko not_active Ceased
- 2013-09-04 EP EP13759995.7A patent/EP2900254B1/en not_active Not-in-force
- 2013-09-04 MX MX2015002604A patent/MX357656B/es active IP Right Grant
- 2013-09-04 CN CN201380043567.0A patent/CN104661673A/zh active Pending
- 2013-09-04 DK DK13759995.7T patent/DK2900254T3/en active
- 2013-09-04 HU HUE13759995A patent/HUE030559T2/en unknown
- 2013-09-04 WO PCT/EP2013/068270 patent/WO2014037390A1/en active Application Filing
- 2013-09-04 AU AU2013311714A patent/AU2013311714C1/en not_active Ceased
- 2013-09-04 NZ NZ629621A patent/NZ629621A/en not_active IP Right Cessation
-
2015
- 2015-01-23 ZA ZA2015/00547A patent/ZA201500547B/en unknown
-
2018
- 2018-08-24 JP JP2018157394A patent/JP2018203756A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014037390A1 (en) | 2014-03-13 |
| ZA201500547B (en) | 2017-09-27 |
| SG11201500669SA (en) | 2015-02-27 |
| JP2015533790A (ja) | 2015-11-26 |
| EP2900254B1 (en) | 2016-08-03 |
| IN2015DN00515A (en:Method) | 2015-06-26 |
| ES2599034T3 (es) | 2017-01-31 |
| BR112015003957A2 (pt) | 2017-08-08 |
| AU2013311714C1 (en) | 2018-01-25 |
| PT2900254T (pt) | 2016-10-18 |
| CN104661673A (zh) | 2015-05-27 |
| MX2015002604A (es) | 2015-06-10 |
| EA028963B1 (ru) | 2018-01-31 |
| HRP20161364T1 (hr) | 2016-12-16 |
| DK2900254T3 (en) | 2016-08-29 |
| NZ629621A (en) | 2015-09-25 |
| HK1210585A1 (en) | 2016-04-29 |
| EA201590503A1 (ru) | 2015-06-30 |
| KR20150047510A (ko) | 2015-05-04 |
| AU2013311714A1 (en) | 2015-03-12 |
| US20150258171A1 (en) | 2015-09-17 |
| EP2900254A1 (en) | 2015-08-05 |
| JP2018203756A (ja) | 2018-12-27 |
| HUE030559T2 (en) | 2017-05-29 |
| CA2881321A1 (en) | 2014-03-13 |
| AU2013311714B2 (en) | 2017-10-12 |
| US10226507B2 (en) | 2019-03-12 |
| MX357656B (es) | 2018-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2991670B8 (en) | Sobetirome in the treatment of myelination diseases | |
| GB201115711D0 (en) | Phyto-cannabinoids for use in the treatment of cancer | |
| IL239368A0 (en) | Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system | |
| DK3292875T3 (en) | Compositions and methods for treating diseases | |
| ZA201500547B (en) | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases | |
| SG10201703677VA (en) | Methods of treating s. aureus-associated diseases | |
| ZA201503979B (en) | Treatment of diseases involving mucin | |
| EP2825194A4 (en) | USE OF ANTITHROMBINE IN THE TREATMENT OF PRE-ECLAMPSIA | |
| AU348530S (en) | Wheelchair | |
| GB2515440B (en) | Vesicular Formulations for use in the treatment of Rosacea | |
| ZA201307058B (en) | Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment | |
| SI2872176T1 (sl) | Karboranilporfirin za uporabo pri zdravljenju raka | |
| IL239078A0 (en) | Protein for use in the treatment of eye diseases | |
| ZA201308176B (en) | Therapeutic treatment | |
| GB201215502D0 (en) | Medical use | |
| GB201322272D0 (en) | Catheter and process for cleaning the catheter | |
| AU2012903356A0 (en) | Improvements in Medical Treatment | |
| AU2012905519A0 (en) | Treatment of diseases involving mucin | |
| GB201211135D0 (en) | Treatment | |
| GB201208690D0 (en) | Treatment | |
| AU2012900796A0 (en) | Pain treatment | |
| GB201204645D0 (en) | Treatment of disease | |
| GB201212604D0 (en) | New treatment | |
| GB201205449D0 (en) | Treatment process |